KULA 101Alternative Names: KULA101
Latest Information Update: 11 Dec 2015
At a glance
- Originator Partikula
- Class Small molecules
- Mechanism of Action CD223 antigen inhibitors; CD4 antigen inhibitors; CD4-positive T lymphocyte stimulants; CD8 antigen inhibitors; CD8 positive T lymphocyte stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors; HAVCR2 protein inhibitors; PDCD 1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 04 Dec 2015 Preclinical trials in Cancer in USA (unspecified route)